Aptevo Therapeutics EBITDA 2014-2022 | APVO

Aptevo Therapeutics ebitda from 2014 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Aptevo Therapeutics Annual EBITDA
(Millions of US $)
2021 $-20
2020 $-26
2019 $-39
2018 $-49
2017 $-51
2016 $-135
2015 $-58
2014 $-49
2013 $1
Aptevo Therapeutics Quarterly EBITDA
(Millions of US $)
2022-03-31 $-5
2021-12-31 $-4
2021-09-30 $-4
2021-06-30 $-5
2021-03-31 $-7
2020-12-31 $-6
2020-09-30 $-6
2020-06-30 $-6
2020-03-31 $-7
2019-12-31 $-7
2019-09-30 $-11
2019-06-30 $-10
2019-03-31 $-11
2018-12-31 $-13
2018-09-30 $-12
2018-06-30 $-12
2018-03-31 $-13
2017-12-31 $-17
2017-09-30 $-9
2017-06-30 $-14
2017-03-31 $-11
2016-12-31 $-22
2016-09-30 $-89
2016-06-30 $-12
2016-03-31 $-12
2015-12-31
2015-09-30 $-12
2015-06-30 $-18
2014-12-31
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.018B $0.012B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00